Get started
Author

Monica Milano

Observed names: M Milano, M. Milano
Observed institutions: University of Milan, Luigi Sacco Hospital, Federico II University Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, European Institute of Oncology, University of Naples Federico II
ORCID: 0000-0003-0983-1604
Observed ORCID: 0000-0003-0983-1604
OpenAlex ID: A5088042472
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
2019 · Claudio Vernieri, Monica Milano, et al. · Critical Reviews in Oncology/Hematology · 240
Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies
2015 · Angela Esposito, Carmen Criscitiello, et al. · Pharmacology & Therapeutics · 109
Features of aggressive breast cancer
2015 · Grazia Arpino, Monica Milano, et al. · The Breast · 66
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer
2018 · Claudio Vernieri, Alessia Mennitto, et al. · Scientific Reports · 57
PDF
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
2016 · Marta Bonotto, Lorenzo Gerratana, et al. · The Breast · 57
PDF
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond
2016 · Cristina Migali, Monica Milano, et al. · Therapeutic Advances in Medical Oncology · 43
Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
2016 · Piera Gargiulo, Matilde Pensabene, et al. · BMC Cancer · 42
PDF
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
2023 · Chiara A. Cella, Maren Knoedler, et al. · JAMA Network Open · 24
PDF
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles
2018 · Claudio Vernieri, Michele Prisciandaro, et al. · Clinical Breast Cancer · 19
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020 · Margaret Ottaviano, Marcello Curvietto, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
2021 · Silvia Dellapasqua, Pamela Trillo Aliaga, et al. · Current Oncology · 15
PDF
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study
2017 · Claudio Vernieri, Monica Milano, et al. · Breast Cancer Research and Treatment · 14
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
2024 · Monica Milano, Carmine Valenza, et al. · European Journal of Cancer · 12
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 · G. Antonarelli, M. Milano, et al. · ESMO Open · 11
PDF
Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
2021 · Nadia Bianco, Antonella Palazzo, et al. · The Breast · 6
PDF
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study
2026 · Carmine Valenza, Yue Zheng, et al. · Journal of Clinical Oncology · 5
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study
2025 · Nadia Bianco, Carmine Valenza, et al. · The Breast · 4
PDF
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 · C. Valenza, J.D. Etessami, et al. · ESMO Open · 3
Abstract B022: Metabolic and immunologic effects of the fasting mimicking diet in cancer patients
2018 · Filippo de Braud, Claudio Vernieri, et al. · Molecular Cancer Therapeutics · 3
Evaluation of the sensitivity of two highly sensitive troponin assays for early detection of non ST- elevation myocardial infarction (NSTEMI)
2011 · Fabrício Braga, Alberto Dolci, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 3
Extended endocrine therapy after 5 years of adjuvant LHRH-agonist in premenopausal patients with node-positive hormone receptor (HR)-positive early breast cancer.
2025 · Carmine Valenza, Yue Zheng, et al. · Journal of Clinical Oncology · 2
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis
2021 · Nadia Bianco, Monica Milano, et al. · Breast Cancer Research and Treatment · 2
Safety and metabolic effects of cyclic fasting mimicking diet (FMD) in cancer patients.
2018 · Filippo G. De Braud, Monica Milano, et al. · Journal of Clinical Oncology · 2
Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer
2013 · Carmine De Angelis, Monica Milano, et al. · Combination Products in Therapy · 2
PDF
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine
2013 · Carmine De Angelis, Monica Milano, et al. · Tumori Journal · 2
Works count: 61
Citation count: 765
H-index: 12
I10-index: 14
Year
Topic
Type